InsiderTrades.com logo
Protect Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.

1AD Insider Trading

Insider Ownership Percentage: 45.91%
Insider Buying (Last 12 Months): A$2,200.00
Insider Selling (Last 12 Months): A$0.00

AdAlta Insider Trading History Chart

This chart shows the insider buying and selling history at AdAlta by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

AdAlta Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for 1AD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Watch this before it gets removed
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.

AdAlta Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/6/2024Timothy OldhamInsiderBuy100,000A$0.02A$2,200.00
10/26/2021Timothy OldhamInsiderBuy235,000A$0.09A$19,975.00
See Full Table
625,000% Gain
From Crypto Swap Profits   |   Ad
The recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull run is over. But if history has taught us anything, it’s that this is only the beginning.
>> Dive into the Workshop Here

SEC Filings (Institutional Ownership Changes) for AdAlta (ASX:1AD)

14.33% of AdAlta stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

AdAlta logo
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics by its i-body platform in Australia. Its lead product is AD-214, an antibody therapeutic, which is in Phase I clinical trial for the treatment of fibrotic diseases, including idiopathic pulmonary fibrosis and interstitial lung disease, kidney fibrosis, eye fibrosis, and various cancers. AdAlta Limited has collaborative partnerships with GE Healthcare to develop i-body enabled granzyme B PET imaging agents for use in immuno-oncology; and Carina Biotech to develop CAR-T cell products against various solid tumor antigens. The company was incorporated in 2006 and is based in Bundoora, Australia.
Read More on AdAlta

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

135,957 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Who are the company insiders with the largest holdings of AdAlta?

AdAlta's top insider investors include:
  1. Timothy Oldham (Insider)
Learn More about top insider investors at AdAlta.
Protect Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.